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Abstract: Coronary artery disease (CAD) and myocardial infarction (MI) are recognized as leading
causes of mortality in developed countries. Although typically associated with behavioral risk factors,
such as smoking, sedentary lifestyle, and poor dietary habits, such vascular phenotypes have also
long been recognized as being related to genetic background. We review the currently available
data concerning genetic markers for CAD in English and non-English articles with English abstracts
published between 2003 and 2018. As genetic testing is increasingly available, it may be possible to
identify adequate genetic markers representing the risk profile and to use them in a clinical setting.
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1. Introduction
Coronary artery disease (CAD) and myocardial infarction (MI) are recognized as leading causes
of mortality in developed countries [1]. Although typically associated with behavioral risk factors such
as smoking, sedentary lifestyle, and poor dietary habits, such vascular phenotypes are also strongly
related to genetic background. Based on population and sibling studies, it has been estimated that
40–60% of susceptibility to CAD can be attributed to genetic factors [2,3].
The measurement of genetic markers is nowadays non-invasive, which makes detection of a
genetic predisposition for CAD easier. The measuring of such markers is convenient for screening for
high-risk individuals very early in life. Also, contrary to circulating biomarkers like cholesterol or
triglycerides, genetic markers are not prone to fluctuations. Timely screening could, therefore, allow for
better prevention strategies (drug and lifestyle modifications). Given that early modification of risk
factors can postpone or prevent the disease [4], it seems reasonable to evaluate genetic variations
associated with changeable risk factors such as blood pressure and blood lipid levels.
To create therapies that are effective in CAD treatment, it is of most importance to improve our
understanding of numerous genetic, as well as epigenetic cues for the onset and development of heart
failure [5,6].
Today several commercial companies offer genetic panels for common diseases, including
atherosclerosis. The true utility of these tests, however, is a matter for discussion.
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We anticipate that risk prediction models that incorporate both genetic factors and traditional
clinical biomarkers would enable a more reliable estimation of cardiovascular risk and justify
preventive measures for individuals at risk.
2. Familial Hypercholesterolemia (FH)
The primary monogenic disease-assuring predisposition to atherosclerosis and CAD is familial
hypercholesterolemia (FH). FH is one of the most common genetic disorders, and it is characterized by
elevated levels of low-density lipoprotein (LDL)-cholesterol (LDL-C) [7]. This is an inherited disease
where a single mutation can lead to a very high risk for atherosclerotic plaque development and
premature MI [8].
FH is still diagnosed primarily by one’s peripheral blood lipid profile and family history.
While genetic screening has not yet been universally adopted, it is recommended, but not mandatory,
in the Netherlands, Norway, and United Kingdom [9]. Also, the Simon-Broome criteria and The
Dutch Clinical Lipid Network criteria for the diagnosis of FH require a functional genetic mutation
as well [10,11]. In the United States, the American Heart Association (AHA) encourages genetic
testing [12], while the US Medical Pedigrees with FH to Make Early Diagnoses and Prevent Early Death
(MEDPED) has not yet adopted this recommendation [13]. Practice shows that the implementation of
strategies for identification of individuals with FH at the population scale has proven difficult, making
FH both underdiagnosed and undertreated [11]. Apart from cost and logistical concerns, large genetic
screening is additionally complicated by the fact that knowing the mutation status of the individual
is not sufficient for diagnosis. Not all carriers of FH mutation manifest severely elevated cholesterol
levels [14]. A study [14] showed that 27% of these individuals had normal LDL-C concentrations
(suggesting incomplete penetrance of the mutation). On the other hand, among individuals diagnosed
with severe hypercholesterolemia, having LDL-C level ≥ 190 mg/dL (4.91 mmol/L), only 2% were
carriers of FH mutations [15]. These data imply that monogenic disorders account for a very small
portion of diagnosed cases of atherosclerosis-related diseases. The majority of cases are polygenic,
resulting from complex interactions among genetic, epigenetic, and environmental factors [16–18].
The candidate gene approach pinpoints several mutations responsible for FH and consequently
CAD (Figure 1): A mutation in the LDL receptor (LDLR), a mutation in apolipoprotein B (ApoB),
a gain of function mutation in proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, and null
mutations in the genes encoding LDLR adaptor protein 1 (LDLRAP1) and ATP-binding cassette
sub-family G (ABCG) member 5 (ABCG5) or member 8 ABCG8 (Figure 1) [19].
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Figure 1. The candidate genes for genetic markers of FH and consequently CAD. ABCG5—ATP-binding
cassette sub-family G member 5 (or ABCG8); ApoB—Apolipoprotein B; CAD—coronary artery disease;
FH familial hypercholesterolemia; LDLR low-density lipoprotein receptor; LDLRAP1—LDLR
adaptor protein 1; PCSK9 Proprotein convertase subtilisin/kexin type 9.
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3. Genetic Markers for CAD
Genetic epidemiologic methods for recognition of candidates for complex traits follow two main
approaches. A hypothesis-driven approach explores a potential candidate gene or a pathway with
a large effect on disease development, while a hypothesis-free approach relies on population-based
studies like genome-wide and rare-variant association studies [20].
The hypothesis-driven approach relies on prior knowledge of the disease aetiology. These studies
usually focus on deleterious loss-of-function mutations that follow the Mendelian pattern of
inheritance [21,22]. The disadvantage of candidate gene analysis is the lessened possibility for detection
of new genetic variants or novel genes. In addition, genes with small or modest effect on disease
course can be missed [20,23].
A hypothesis-free study design uses large cohorts of unrelated individuals that are genotyped
at millions of single nucleotide polymorphisms (SNPs) across the genome. The accomplishments of
the Human Genome Project and the HapMap project, combined with the development of large-scale
genotyping methods supported by statistical and computational approaches, enabled large-scale
Genome-wide association studies (GWAS), in which a large number of genetic variants are investigated
in a search for links with the trait of interest [24]. GWAS is extremely successful, making up to
2,000,000 genetic variants available for association analysis with a given phenotype [25]. Additionally,
GWAS analysis is unbiased by previous knowledge and is therefore useful for detecting novel
unsuspected gene candidates.
More recently, next-generation sequencing (NGS) technologies have also enabled the “rare variant
association study” (RVAS). Genetic variants that are too rare to be detected by GWAS are aggregated
into subsets, and their frequency is compared between patients and controls [26].
4. Low-Density Lipoprotein Receptor (LDLR)
In the body, the principal receptor responsible for clearance of LDL-C from blood circulation is
hepatic LDLR [27]. LDL-C binds LDLR and forms LDL-C/LDLR complexes that undergo endocytosis
within clathrin-coated vesicles [28,29]. After translocation to the cytoplasm, LDL-C separates from
LDLR, and it is subject to further degradation, while LDLR rapidly recycles and folds back to the cell
surface [28,29]. The mechanism of LDL-C uptake by the LDLR is a very specific process, and it is
influenced by various hereditary and environmental factors [27,30]. FH and its consequences [31,32]
can be caused by mutations in the LDLR gene. There are several gene mutations of the LDLR
that lead to mild or severity FH, such as mutations that affect the synthesis of the LDLR in the
endoplasmic reticulum, mutations that disable proper transport of LDLR to the Golgi apparatus,
mutations that disable binding of LDL-C to the LDLR, mutations that disable the receptor-ligand
complex internationalization, and mutations that disable proper recycling of LDLR [31–33]. In addition,
the PCSK9 indirectly controls the level of LDL-C in the blood by binding to the epidermal growth
factor-like repeat homology domain (EGF-A) of the LDLR in the liver, which leads to endocytosis and
LDLR destruction [34].
5. Apolipoprotein B (ApoB)
ApoB is an essential structural protein component of all atherogenic or potentially
atherogenic lipoprotein particles, including chylomicrons, very-low-density lipoprotein (VLDL),
intermediate-density lipoprotein (IDL), LDL, and lipoprotein (a) (Lp(a)) [35,36]. Each of the particles
mentioned above contains one molecule of ApoB [35,36]. The concentration of atherogenic particles
can be accurately estimated by measuring the plasma level of this apolipoprotein [34]. ApoB remains
anchored to the lipoproteins without undergoing any changes [37]. Therefore, an increased plasma
ApoB concentration is an important risk factor/predictor of CAD [35,36]. ApoB provides a direct
measure of the number of atherogenic lipoprotein particles in circulation. The majority of the
total plasma ApoB is bound to LDL, which makes ApoB a good substitute for LDL particle
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concentration [35,38]. Higher ApoB lipoprotein particles may be less atherogenic than the smaller,
denser LDL particles. Therefore, the measurement of the level of ApoB in LDL particles is a
better predictor of atherogenesis than the total serum ApoB level, although this is not documented
in all published studies [35,39–42]. ApoB is assumed to be a superior marker for lipoprotein
abnormalities [36]. The blood level of ApoB in patients with CVD has been shown to be a better
discriminator than HDL-C and LDL-C levels.
ApoB is present in plasma as two main isoforms, ApoB-48 and ApoB-100 [43]. The Apo-48 is
exclusively found in the gut, and the Apo-100 is found in the liver [44]. The intestinal and the hepatic
forms of ApoB are encoded by a single gene, which gets transcribed into long mRNA [45,46].
ApoB-100 is a predominant structural apolipoprotein of LDL particles, and it binds to LDLR and
mediates hepatic LDL-C uptake. Therefore, it is expected that mutations in ApoB and LDLR affect
the level of cholesterol and lead to hypercholesterolemia and the development and progression of
CVD [47].
6. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
PCSK9 is a crucial modulator of LDLR levels and plasma LDL-C [48]. Deficiency in PCSK9 leads
to considerably lowered LDL-C levels in humans and protects against CAD [49,50].
In the 1960s and 1970s, it was established that bioactive secretory proteins (hormones and
enzymes) initially are synthesized as inactive precursors which are transformed into active products
by limited proteolysis [51]. This introduced the concept that conversion of an inactive precursor into
the product which fulfils its function is catalyzed by a special group of proteases called proprotein
convertase. PCSK9 binds to the LDLR and enables its degradation, which leads to a decrease of LDL-C
and an increased risk of atherosclerosis. As a result, PCSK9 emerged as a promising therapeutic
strategy for the treatment of hypercholesterolemia and atherosclerosis.
The gene which encodes for the PCSK9 is located on chromosome 1 [52,53] and encodes for the
member of the subtilisin-like proprotein convertase family that activates other proteins, and its coding
region is comprised of 13 exons [52]. In 2003, through the protein BLAST program [54], a putative
convertase called neural apoptotic-regulated convertase 1 (NARC-1), which belongs to the proteinase
L subfamily of subtilases, was identified [55]. At the same time, a research group in Paris (Necker
Hospital) studied families with FH, the genetic form of an extremely high level of LDL-C caused by
the expression of the gene on the short arm of chromosome 1 [56], which leads to the development of
severe CAD, often resulting in premature death.
Most therapeutic approaches to hypercholesterolemia involve cholesterol biosynthesis inhibition
and upregulation of LDLR in the liver. The analysis [57] of 1183 patients was conducted and showed
that with statin treatment there is a large reduction in LDL-C down to 60 mg/dL (1.55 mmol/L).
People with mutations in ApoB and LDLR can develop hypercholesterolemia, as can people with
mutations in both ATP-binding cassette transporters (ABCG5 and ABCG8) and the gene called
autosomal recessive hypercholesterolemia, which encodes for the LDLR adaptor protein called
PCSK9 [58]. Mutations in the PSCK9 were first described in the family of persons who developed
FH [30,56]. The link between PCSK9 and cholesterol metabolism was followed by the discovery of
selected mutations in the gene and the observation that PCSK9 was regulated by cholesterol [59].
7. LDLR Adaptor Protein 1 (LDLRAP1)
Autosomal recessive hypercholesterolemia is a very rare disorder (mostly in Italians) caused
by a mutation in the LDLRAP1 gene [60,61]. LDLRAP1 (previously termed autosomal recessive
hypercholesterolemia (ARH)) is the protein involved in regulation of proper traffic and recycling
processes of LDLR [60,61]. This adapter protein contains a phosphotyrosine binding (PTB) domain
that recognizes and binds to a conserved tyrosine phosphorylation motif (Asn-Pro-X-Tyr) where X
is any amino acid (NPXY motifs) of membrane receptors, including LDLR [60,61]. Defects in mature
LDLRAP1 caused by mutations of that gene lead to incorrect LDL uptake of hepatocytes, resulting in
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hypercholesterolemia. Unlike patients with a homozygous genotype, clinical presentation in patients
with a heterozygous genotype often have a normal level of cholesterol in the circulation [13,61,62].
8. Adiponectin
Adiponectin is one of the most abundant adipocyte-derived secretory proteins in human visceral
fat tissues. Circulating levels of adiponectin are negatively correlated with the percentage of
human visceral fat mass [63]. Adiponectin is a 247-amino-acids-long protein with structural and
sequence homology (43%) with tumor necrosis factor-α, and complement protein C1q Adiponectin
is composed of three domains: a signal sequence located at the N-terminus, a collagen-like domain,
and a globular C terminal domain [64]. In the circulation, adiponectin exists as the hexamer called
low molecular weight oligomer (HMW), which is composed of four to six trimmers (the active
form of adiponectin) [65]. HMW oligomers are part of the intracellular adiponectin, while within
circulation, adiponectin is represented as the low molecular weight oligomers. Circulating adiponectin
represents 0.05% of total serum protein [2], and usual concentrations in the circulation are between
2 and 20 µg/mL−1. High plasma levels of adiponectin are related to insulin sensitivity in a
healthy population [3]. Lower levels of adiponectin are a risk for development of diabetes [66],
CAD, and hypertension [67,68]. Adiponectin exerts atheroprotective characteristics and has
inverse relations with CAD [6]. Adiponectin modulates the interaction between classical risk
factors and atherosclerosis [69]. Levels of adiponectin are lower in patients with cardiovascular
diseases, and lowered levels of adiponectin can be a predictor of the development of myocardial
infraction [66–68]. Adiponectin is a cardioprotective protein, yet its association with the atherosclerotic
severity and predictive power for CAD remains controversial in different populations, most likely due
to racial/ethnic differences, lifestyles, and environmental factors [70–72]. Plasma concentrations of
adiponectin and HMW adiponectin might be useful as the early biomarkers of cardiovascular risk in
general and also a predictor of adverse cardiovascular events in patients with CAD [70,71].
9. C-Reactive Protein (CRP)
C-reactive protein (CRP) is an acute phase protein synthesized in the liver and the vascular
endothelium, and it belongs to the family of pentraxins. In atherosclerotic plaques, CRP is present
with monocytes and lipoproteins [73]. CRP activates the process of phagocytosis, which clears necrotic
tissues in the atherosclerotic plaques and perpetuates inflammatory response [74]. There are indications
that persons with no manifestations of vascular disease and elevated CRP have a 3–4 fold increased
relative risk of myocardial infarction [75]. In a large meta-analysis on subjects with no history of
vascular disease, CRP was connected with a risk of CAD and ischemic stroke [76]. Elevated CRP
is associated with an increased risk of CAD events in apparently healthy individuals [77], and its
elevated levels are strongly associated with the risk of fatal CAD outcomes. Baseline levels of CRP are
elevated in patients with unstable angina and are associated with an unfavorable short-term prognosis.
CRP levels might be a valid prognostic marker for differentiation between patients with unstable
angina and chronic stable angina; however, they fail to differentiate patients with stable CAD from
patients with acute coronary syndrome [78].
In patients with an angiographically evaluated CAD, levels of high-sensitivity CRP (hs-CRP) are
significantly higher compared to healthy individuals, and they correlate with the severity and presence
of the CAD [79]. There are undoubtedly advantages to hs-CRP measurements for CAD detection and
evaluation. CRP is a stable protein, and its levels can be measured at any time of the day without
special relevance to the biological clock [74,80].
10. Ion Channels
The alternated or disturbed regulation of the coronary blood flow can lead to CAD. Ion channels
are key effectors of the regulatory mechanism, and certain variations in genes encoding for ion channel
proteins may affect the coronary blood flow [81]. Polymorphisms in ion channel genes are also
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recognized as contributors to diabetes mellitus, which is one of the most powerful cardiovascular risk
factors [82,83]. Evaluation of the clinical impact of these SNPs showed that polymorphism detected in
nitric oxide synthase (NOS) 3 gene (NOS3), which encodes for endothelial NOS (eNOS), are correlated
with ischemic heart disease [84]. The SNP rs1805124_GG for a sodium channel alpha-subunit gene
(SCN5A) of the voltage-gated sodium channel, Nav, is more frequently observed in patients with
CAD [84]. SNPs in ATP-sensitive potassium channel (KATP) subunits KCNJ8 (Kir6.1) and ABCC9
(SUR2) [83] might influence the presence of diabetes, and they seem to be involved in ischemic heart
disease pathogenesis. However, the mechanisms of this effect are still unclear.
11. GWAS Analysis and CAD
To uncover multiple loci spanning the entire genome responsible for the onset of atherosclerosis,
large-scale GWAS studies were performed [85,86]. GWAS analysis allows for simultaneous and
accurate genotyping of up to 1 million SNPs. For each SNP, individuals with one genotype are
compared with individuals with another genotype to assess whether there is a phenotypic difference.
GWAS studies require very large samples, which permit detection of alleles with low incremental risk.
This called for the establishment of large international collaborations in the field of cardiology.
The international consortium, CARDIoGRAM (Coronary Artery Disease Genome-Wide Replication
and Meta-Analysis), is the biggest such alliance to date, and it has analyzed more than 200,000 cases
and control subjects of European ancestry. Apart from sufficient sample size, this collaboration
brought together resources and researchers from United States, Canada, United Kingdom, Germany,
and Iceland. The group identified 62 loci associated with predisposition to CAD, which were
subsequently confirmed in a different population [87].
Interestingly, only 20% of the loci were spotted in proximity to the genes with known roles
in the metabolism of LDL or triglyceride-rich lipoproteins (TRLs). An additional 5–10% of the
loci regulate vascular tone or platelet aggregation [85]. These findings further confirmed the
importance of already recognized contributors, but interestingly, some unsuspecting candidates
emerged. Genes involved in focal adhesion/extracellular matrix interaction, transforming growth
factor beta (TGF-β) signalling, apoptosis, angiogenesis, and transcriptional processes, whose role is not
entirely clear, were significant [88]. Moreover, the spotted SNPs are supposed to have cumulative or
synergistic effects because, taken singly, each one of them has a minimal or modest effect. The relative
increased risk of each genetic variant for CAD averages only 18% [89]. The genetic risk for CAD seems
much more associated with the number of inherited risk variants than with the power of any one
genetic variant alone.
However, the majority of SNPs detected by GWAS are not in coding sequences, and the
mechanisms underlying these associations are less than obvious [90]. They may exert functional
consequences if they are localized in the promoter regions or through mRNA silencing. This implies
that there are more unknown mechanisms contributing to the pathogenesis of CAD than suspected.
These genetic variants occur very frequently, about half occurring in 50% of the population and a
quarter in more than 75% of the population, whereas they cumulatively explain only 30–40% of CAD
heritability [85,91].
A series of reports documented that one such SNP is in the 9p21.3 locus [90,92]. Approximately
75% of the European population carries this locus, and it is independent of any conventional risk
factor for CAD. 25% of Europeans that carry two copies of this SNP have a 40% increased risk of
atherosclerosis [93,94]. The association of this locus with the atherosclerotic phenotype was confirmed
in independent studies and among different ethnic groups. The same variants have been linked to
both abdominal aortic and intracranial arterial aneurysms, suggesting its possible effects on vascular
wall integrity [95].
Some evidence indicates that the 9p21 is a part of the long non-coding RNA (lncRNA) antisense
noncoding RNA in the INK4 locus (ANRIL), which affects the activity of two nearby cyclin-dependent
kinase (CDK) inhibitors, 2A (CDKN2A) and 2B (CDKN2B) [68,69]. Because the 9p21 risk variant is
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not present in the mouse genome, it is difficult to determine its function, and the precise mechanism
underlying the 9p21 association with CAD remains vague.
GWAS analysis showed an association of genetic factors with only a small number of disease
phenotypes. The genetic variants have relatively low effect sizes and explain up to 40% of population
variation. This leaves the best part of heritability unknown, possibly due to missing gene-environment
interactions [96,97]. The findings of Cole et al. [98], that genetic risk for dyslipidemia is positively
associated with adiposity, imply the necessity of screening for other lifestyle predictors that may
enhance gene variants effects, such as physical activity, smoking, and alcohol intake.
Several groups have made an effort to translate the genetic risk burden identified by GWAS into a
single value, a genetic risk score (GRS), which is convenient for patient stratification [99,100]. A GRS
depends on both the number of high-risk variants inherited and the log of the odds interval previously
determined. These studies suggest that GRS is independent and more accurate than traditional risk
factors. A prospective trial showed individuals with a high GRS had a 91% greater risk of cardiac
events [89]. The study of Mega et al. [101] demonstrated that a high GRS is not only associated
with the incident of CAD events but also foresaw recurrent disease. A subsequent study analyzed
23 additional SNPs and showed even more improved discrimination and reclassification than the
study of Tada et al. [102]. Individuals with high GRS had a 2.4-fold greater risk than those with low
GRS. Other studies that included even more loci report further enhancement of the power of predicting
cardiac events [103,104].
However, the high cost of genotyping, and the widespread use of Framingham or American
College of Cardiology/American Heart Association (ACC/AHA) risk scores that already perform
quite well, makes it difficult to demonstrate sufficient improvement in patient management [105,106].
12. Conclusions
Given the complex genetic background of vascular diseases, including family history in the
initial medical evaluation appears reasonable. In cases where first-degree relatives are affected and
inheritance patterns hint at monogenic disorders, investigational clinical studies show that genetic
testing is justified. In other cases, however, testing for genetic factors still offers little advantage over
the examination of traditional risk factors.
Author Contributions: N.V., D.R., and E.R.I. contributed to the conception and design of the work. I.M., B.Z.,
M.O., and E.S.-M. contributed to the acquisition of data for the work. N.V., B.Z., M.O., and E.S.-M. contributed
to the analysis of data for the work. N.V., I.M., B.Z., M.O., and E.S.-M. contributed to the interpretation of data
for the work. N.V., I.M., B.Z., M.O., and E.S.-M. drafted the manuscript. D.R. and E.R.I. critically revised the
manuscript. All authors gave final approval and agreed to be accountable for all aspects of work ensuring integrity
and accuracy.
Acknowledgments: The author(s) disclosed receipt of the following financial support for the research, authorship,
and/or publication of this article: this work was supported by grants No. 173001 (to N.V.), No. 41002 (to D.R.), and
No. 173033 (to E.R.I.) from the Ministry of Education, Science and Technological Development, Republic of Serbia.
Conflicts of Interest: The authors declared no potential conflicts of interest concerning the research, authorship,
and publication of this article.
References
1. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.;
Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:
A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2095–2128. [CrossRef]
2. Marenberg, M.E.; Risch, N.; Berkman, L.F.; Floderus, B.; De Faire, U. Genetic susceptibility to death from
coronary heart disease in a study of twins. N. Engl. J. Med. 1994, 330, 1041–1046. [CrossRef] [PubMed]
3. Zdravkovic, S.; Wienke, A.; Pedersen, N.L.; Marenberg, M.E.; Yashin, A.I.; De Faire, U. Heritability of death
from coronary heart disease: A 36-year follow-up of 20 966 Swedish twins. J. Intern. Med. 2002, 252, 247–254.
[CrossRef] [PubMed]
Medicina 2018, 54, 36 8 of 13
4. Catapano, A.L.; Lautsch, D.; Tokgozoglu, L.; Ferrieres, J.; Horack, M.; Farnier, M.; Toth, P.P.; Brudi, P.;
Tomassini, J.E.; Ambegaonkar, B.; et al. Prevalence of potential familial hypercholesteremia (FH) in
54,811 statin-treated patients in clinical practice. Atherosclerosis 2016, 252, 1–8. [CrossRef] [PubMed]
5. Ren, J.; Zhang, Y. Emerging Therapeutic Potential Targeting Genetics and Epigentics in Heart Failure.
Biochim. Biophys. Acta 2017, 1863, 1867–1869. [CrossRef] [PubMed]
6. Zhang, Y.; Ren, J. Epigenetics and obesity cardiomyopathy: From pathophysiology to prevention and
management. Pharmacol. Ther. 2016, 161, 52–66. [CrossRef] [PubMed]
7. Reiner, Z. Management of patients with familial hypercholesterolaemia. Nat. Rev. Cardiol. 2015, 12, 565–575.
[CrossRef] [PubMed]
8. Austin, M.A.; Hutter, C.M.; Zimmern, R.L.; Humphries, S.E. Genetic causes of monogenic heterozygous
familial hypercholesterolemia: A HuGE prevalence review. Am. J. Epidemiol. 2004, 160, 407–420. [CrossRef]
[PubMed]
9. Paynter, N.P.; Ridker, P.M.; Chasman, D.I. Are Genetic Tests for Atherosclerosis Ready for Routine Clinical
Use? Circ. Res. 2016, 118, 607–619. [CrossRef] [PubMed]
10. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on
behalf of the Simon Broome Register Group. BMJ 1991, 303, 893–896.
11. Nordestgaard, B.G.; Chapman, M.J.; Humphries, S.E.; Ginsberg, H.N.; Masana, L.; Descamps, O.S.;
Wiklund, O.; Hegele, R.A.; Raal, F.J.; Defesche, J.C.; et al. Familial hypercholesterolaemia is underdiagnosed
and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease:
Consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013, 34, 15. [CrossRef] [PubMed]
12. Gidding, S.S.; Champagne, M.A.; De Ferranti, S.D.; Defesche, J.; Ito, M.K.; Knowles, J.W.; Mccrindle, B.;
Raal, F.; Rader, D.; Santos, R.D.; et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement
from the American Heart Association. Circulation 2015, 132, 2167–2192. [CrossRef] [PubMed]
13. Henderson, R.; O’kane, M.; Mcgilligan, V.; Watterson, S. The genetics and screening of familial
hypercholesterolaemia. J. Biomed. Sci. 2016, 23, 39. [CrossRef] [PubMed]
14. Rabes, J.; Varret, M.; Devillers, M.; Aegerter, P.; Villéger, L.; Krempf, M.; Junien, C.; Boileau, C.; Rabes, J.P.;
Varret, M.; et al. R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia.
Arterioscler. Thromb. Vasc. Biol. 2000, 20, E76–E82. [CrossRef] [PubMed]
15. Khera, A.V.; Won, H.H.; Peloso, G.M.; Lawson, K.S.; Bartz, T.M.; Deng, X.; Van Leeuwen, E.M.;
Natarajan, P.; Emdin, C.A.; Bick, A.G.; et al. Diagnostic Yield and Clinical Utility of Sequencing Familial
Hypercholesterolemia Genes in Patients with Severe Hypercholesterolemia. J. Am. Coll. Cardiol. 2016, 67,
2578–2589. [CrossRef] [PubMed]
16. Sijbrands, E.J.G.; Westendorp, R.G.J.; Defesche, J.C.; De Meier, P.H.E.M.; Smelt, A.H.M.; Kastelein, J.J.P.
Mortality over two centuries in large pedigree with familial hypercholesterolaemia: Family tree mortality
study. BMJ Br. Med. J. 2001, 322, 1019–1023. [CrossRef]
17. Hill, J.; Hayden, M.; Frohlich, J.; Pritchard, P. Genetic and environmental factors affecting the incidence
of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler. Thromb. 1991, 11,
290–297. [CrossRef] [PubMed]
18. Turgeon, P.J.; Sukumar, A.N.; Marsden, P.A. Epigenetics of Cardiovascular Disease-A New “Beat” in
Coronary Artery Disease. Med. Epigenet. 2014, 2, 37–52. [CrossRef] [PubMed]
19. Musunuru, K.; Kathiresan, S. Genetics of coronary artery disease. Annu. Rev. Genom. Hum. Genet. 2010, 11,
91–108. [CrossRef] [PubMed]
20. Zhu, M.; Zhao, S. Candidate gene identification approach: Progress and challenges. Int. J. Biol. Sci. 2007, 3,
420–427. [CrossRef] [PubMed]
21. Natarajan, P.; Kohli, P.; Baber, U.; Nguyen, K.H.; Sartori, S.; Reilly, D.F.; Mehran, R.; Muntendam, P.; Fuster, V.;
Rader, D.J.; et al. Association of APOC3 Loss-of-Function Mutations with Plasma Lipids and Subclinical
Atherosclerosis: The Multi-Ethnic BioImage Study. J. Am. Coll. Cardiol. 2015, 66, 2053–2055. [CrossRef]
[PubMed]
22. Glisic, S.; Arrigo, P.; Alavantic, D.; Perovic, V.; Prljic, J.; Veljkovic, N. Lipoprotein lipase: A bioinformatics
criterion for assessment of mutations as a risk factor for cardiovascular disease. Proteins 2008, 70, 855–862.
[CrossRef] [PubMed]
Medicina 2018, 54, 36 9 of 13
23. Isaacs, A.; Willems, S.M.; Bos, D.; Dehghan, A.; Hofman, A.; Ikram, M.A.; Uitterlinden, A.G.; Oostra, B.A.;
Franco, O.H.; Witteman, J.C.; et al. Risk scores of common genetic variants for lipid levels influence
atherosclerosis and incident coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 2233–2239.
[CrossRef] [PubMed]
24. Embl-Eb. The NHGRI-EBI Catalog of Published Genome-Wide Association Studies. 2018. Available online:
https://www.ebi.ac.uk/gwas/home (accessed on 23 June 2017).
25. Stranger, B.E.; Stahl, E.A.; Raj, T. Progress and promise of genome-wide association studies for human
complex trait genetics. Genetics 2011, 187, 367–383. [CrossRef] [PubMed]
26. Lee, S.; Abecasis, G.R.; Boehnke, M.; Lin, X. Rare-variant association analysis: Study designs and statistical
tests. Am. J. Hum. Genet. 2014, 95, 5–23. [CrossRef] [PubMed]
27. Toth, P.P. The Year in Lipid Disorders, 1st ed.; Oxford Centre for Innovation Mill Street: Oxford, UK, 2010.
28. Beglova, N.; Jeon, H.; Fisher, C.; Blacklow, S.C. Structural features of the low-density lipoprotein receptor
facilitating ligand binding and release. Biochem. Soc. Trans. 2004, 32, 721–723. [CrossRef] [PubMed]
29. Rudenko, G.; Henry, L.; Henderson, K.; Ichtchenko, K.; Brown, M.S.; Goldstein, J.L.; Deisenhofer, J. Structure
of the LDL receptor extracellular domain at endosomal pH. Science 2002, 298, 2353–2358. [CrossRef]
[PubMed]
30. Horton, J.D.; Cohen, J.C.; Hobbs, H.H. Molecular biology of PCSK9: Its role in LDL metabolism.
Trends Biochem. Sci. 2007, 32, 71–77. [CrossRef] [PubMed]
31. North, C.L.; Blacklow, S.C. Solution structure of the sixth LDL-A module of the LDL receptor. Biochemistry
2000, 39, 2564–2571. [CrossRef] [PubMed]
32. Marais, A.D. Familial Hypercholesterolaemia. Clin. Biochem. Rev. 2004, 25, 49–68. [PubMed]
33. Jones, C.; Hammer, R.E.; Li, W.P.; Cohen, J.C.; Hobbs, H.H.; Herz, J. Normal sorting but defective endocytosis
of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia. J. Biol. Chem.
2003, 278, 29024–29030. [CrossRef] [PubMed]
34. Farnier, M. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: Focus on therapeutic
implications. Am. J. Cardiovasc. Drugs 2011, 11, 145–152. [CrossRef] [PubMed]
35. Contois, J.H.; Mcconnell, J.P.; Sethi, A.A.; Csako, G.; Devaraj, S.; Hoefner, D.M.; Warnick, G.R.;
Lipoproteins, A. Vascular Diseases Division Working Group on Best P. Apolipoprotein B and cardiovascular
disease risk: Position statement from the AACC Lipoproteins and Vascular Diseases Division Working
Group on Best Practices. Clin. Chem. 2009, 55, 407–419. [CrossRef] [PubMed]
36. Kaneva, A.M.; Potolitsyna, N.N.; Bojko, E.R.; Odland, J.O. The apolipoprotein B/apolipoprotein A–I ratio as
a potential marker of plasma atherogenicity. Dis. Markers 2015, 2015, 591454. [CrossRef] [PubMed]
37. Sniderman, A.D.; Pedersen, T.; Kjekshus, J. Putting low-density lipoproteins at center stage in atherogenesis.
Am. J. Cardiol. 1997, 79, 64–67. [PubMed]
38. Sniderman, A.; Vu, H.; Cianflone, K. Effect of moderate hypertriglyceridemia on the relation of plasma total
and LDL apo B levels. Atherosclerosis 1991, 89, 109–116. [CrossRef]
39. Vakkilainen, J.; Steiner, G.; Ansquer, J.C.; Aubin, F.; Rattier, S.; Foucher, C.; Hamsten, A.; Taskinen, M.R.
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary
artery disease: The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003, 107, 1733–1737.
[CrossRef] [PubMed]
40. Rizzo, M.; Pernice, V.; Frasheri, A.; Berneis, K. Atherogenic lipoprotein phenotype and LDL size and
subclasses in patients with peripheral arterial disease. Atherosclerosis 2008, 197, 237–241. [CrossRef] [PubMed]
41. St-Pierre, A.C.; Ruel, I.L.; Cantin, B.; Dagenais, G.R.; Bernard, P.M.; Després, J.P.; Lamarche, B. Comparison
of Various Electrophoretic Characteristics of LDL Particles and Their Relationship to the Risk of Ischemic
Heart Disease. Circulation 2001, 104, 2295–2299. [CrossRef] [PubMed]
42. Zambon, A.; Hokanson, J.E.; Brown, B.G.; Brunzell, J.D. Evidence for a New Pathophysiological Mechanism
for Coronary Artery Disease Regression. Circulation 1999, 99, 1959–1964. [CrossRef] [PubMed]
43. Young, S.G. Recent progress in understanding apolipoprotein, B. Circulation 1990, 82, 1574–1594. [CrossRef]
[PubMed]
44. Lo, C.M.; Nordskog, B.K.; Nauli, A.M.; Zheng, S.; Vonlehmden, S.B.; Yang, Q.; Lee, D.; Swift, L.L.;
Davidson, N.O.; Tso, P. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation?
Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294, G344–G352. [CrossRef] [PubMed]
Medicina 2018, 54, 36 10 of 13
45. Chen, S.H.; Li, X.X.; Liao, W.S.; Wu, J.H.; Chan, L. RNA editing of apolipoprotein B mRNA. Sequence
specificity determined by in vitro coupled transcription editing. J. Biol. Chem. 1990, 265, 6811–6816.
[PubMed]
46. Nakamuta, M.; Oka, K.; Krushkal, J.; Kobayashi, K.; Yamamoto, M.; Li, W.H.; Chan, L. Alternative mRNA
splicing and differential promoter utilization determine tissue-specific expression of the apolipoprotein
B mRNA-editing protein (Apobec1) gene in mice. Structure and evolution of Apobec1 and related
nucleoside/nucleotide deaminases. J. Biol. Chem. 1995, 270, 13042–13056. [CrossRef] [PubMed]
47. Goldstein, J.L.; Brown, M.S. A century of cholesterol and coronaries: From plaques to genes to statins. Cell
2015, 161, 161–172. [CrossRef] [PubMed]
48. Banach, M.; Rizzo, M.; Obradovic, M.; Montalto, G.; Rysz, J.; Mikhailidis, D.P.; Isenovic, E.R.
PCSK9 inhibition-a novel mechanism to treat lipid disorders? Curr. Pharm. Des. 2013, 19, 3869–3877.
[CrossRef] [PubMed]
49. Obradovic, M.; Zaric, B.; Sudar-Milovanovic, E.; Ilincic, B.; Perovic, M.; Stokic, E.; Isenovic, E. PCSK9 and
hypercholesterolemia: Therapeutical approach. Curr. Drug Targets 2017, 4. [CrossRef] [PubMed]
50. Katsiki, N.; Giannoukas, A.D.; Athyros, V.G.; Mikhailidis, D.P. Lipid-lowering treatment in peripheral artery
disease. Curr. Opin. Pharmacol. 2018, 39, 19–26. [CrossRef] [PubMed]
51. Seidah, N.G.; Chretien, M. Proprotein and prohormone convertases of the subtilisin family Recent
developments and future perspectives. Trends Endocrinol. MeTable 1992, 3, 133–140. [CrossRef]
52. Zhang, L.; Song, K.; Zhu, M.; Shi, J.; Zhang, H.; Xu, L.; Chen, Y. Proprotein convertase subtilisin/kexin
type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Int. J. Neurosci. 2016, 126, 675–680.
[CrossRef] [PubMed]
53. El Khoury, P.; Elbitar, S.; Ghaleb, Y.; Khalil, Y.A.; Varret, M.; Boileau, C.; Abifadel, M. PCSK9
Mutations in Familial Hypercholesterolemia: From a Groundbreaking Discovery to Anti-PCSK9 Therapies.
Curr. Atheroscler. Rep. 2017, 19, 49. [CrossRef] [PubMed]
54. Basic Local Alignment Search Tool. Available online: www.ncbi.nlm.nih.gov/BLAST (accessed on
23 June 2017).
55. Seidah, N.G.; Benjannet, S.; Wickham, L.; Marcinkiewicz, J.; Jasmin, S.B.; Stifani, S.; Basak, A.; Prat, A.;
Chretien, M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):
Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 2003, 100, 928–933. [CrossRef]
[PubMed]
56. Abifadel, M.; Varret, M.; Rabes, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.;
Wickham, L.; Erlich, D.; et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Nat. Genet. 2003, 34, 154–156. [CrossRef] [PubMed]
57. Nissen, S.E.; Nicholls, S.J.; Sipahi, I.; Libby, P.; Raichlen, J.S.; Ballantyne, C.M.; Davignon, J.; Erbel, R.;
Fruchart, J.C.; Tardif, J.C.; et al. Effect of very high-intensity statin therapy on regression of coronary
atherosclerosis: The ASTEROID trial. JAMA 2006, 295, 1556–1565. [CrossRef] [PubMed]
58. Goldstein, J.L.; Brown, M.S. Molecular medicine. The cholesterol quartet. Science 2001, 292, 1310–1312.
[CrossRef] [PubMed]
59. Maxwell, K.N.; Soccio, R.E.; Duncan, E.M.; Sehayek, E.; Breslow, J.L. Novel putative SREBP and LXR target
genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 2003, 44, 2109–2119.
[CrossRef] [PubMed]
60. Garcia, C.K.; Wilund, K.; Arca, M.; Zuliani, G.; Fellin, R.; Maioli, M.; Calandra, S.; Bertolini, S.; Cossu, F.;
Grishin, N.; et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor
adaptor protein. Science 2001, 292, 1394–1398. [CrossRef] [PubMed]
61. Mishra, S.K.; Watkins, S.C.; Traub, L.M. The autosomal recessive hypercholesterolemia (ARH) protein
interfaces directly with the clathrin-coat machinery. Proc. Natl. Acad. Sci. USA 2002, 99, 16099–16104.
[CrossRef] [PubMed]
62. Usifo, E.; Leigh, S.E.; Whittall, R.A.; Lench, N.; Taylor, A.; Yeats, C.; Orengo, C.A.; Martin, A.C.; Celli, J.;
Humphries, S.E. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database:
Update and pathological assessment. Ann. Hum. Genet. 2012, 76, 387–401. [CrossRef] [PubMed]
63. Ryo, M.; Nakamura, T.; Kihara, S.; Kumada, M.; Shibazaki, S.; Takahashi, M.; Nagai, M.; Matsuzawa, Y.;
Funahashi, T. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 2004, 68, 975–981. [CrossRef]
[PubMed]
Medicina 2018, 54, 36 11 of 13
64. Lihn, A.S.; Pedersen, S.B.; Richelsen, B. Adiponectin: Action, regulation and association to insulin sensitivity.
Obes. Rev. 2005, 6, 13–21. [CrossRef] [PubMed]
65. Wang, Y.; Zheng, A.; Yan, Y.; Song, F.; Kong, Q.; Qin, S.; Zhang, D. Association between HMW adiponectin,
HMW-total adiponectin ratio and early-onset coronary artery disease in Chinese population. Atherosclerosis
2014, 235, 392–397. [CrossRef] [PubMed]
66. Lindsay, R.S.; Funahashi, T.; Hanson, R.L.; Matsuzawa, Y.; Tanaka, S.; Tataranni, P.A.; Knowler, W.C.;
Krakoff, J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360,
57–58. [CrossRef]
67. Nakamura, Y.; Shimada, K.; Fukuda, D.; Shimada, Y.; Ehara, S.; Hirose, M.; Kataoka, T.; Kamimori, K.;
Shimodozono, S.; Kobayashi, Y.; et al. Implications of plasma concentrations of adiponectin in patients with
coronary artery disease. Heart 2004, 90, 528–533. [CrossRef] [PubMed]
68. Spranger, J.; Kroke, A.; Mohlig, M.; Bergmann, M.M.; Ristow, M.; Boeing, H.; Pfeiffer, A.F. Adiponectin and
protection against type 2 diabetes mellitus. Lancet 2003, 361, 226–228. [CrossRef]
69. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.;
Ouchi, N.; Maeda, K.; et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2
diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1595–1599. [CrossRef] [PubMed]
70. Lim, H.S.; Tayebjee, M.H.; Tan, K.T.; Patel, J.V.; Macfadyen, R.J.; Lip, G.Y. Serum adiponectin in coronary
heart disease: Ethnic differences and relation to coronary artery disease severity. Heart 2005, 91, 1605–1606.
[CrossRef] [PubMed]
71. Khan, U.I.; Wang, D.; Sowers, M.R.; Mancuso, P.; Everson-Rose, S.A.; Scherer, P.E.; Wildman, R.P. Race-ethnic
differences in adipokine levels: The Study of Women’s Health Across the Nation (SWAN). Metabolism 2012,
61, 1261–1269. [CrossRef] [PubMed]
72. Hulver, M.W.; Saleh, O.; Macdonald, K.G.; Pories, W.J.; Barakat, H.A. Ethnic differences in adiponectin levels.
Metabolism 2004, 53, 1–3. [CrossRef] [PubMed]
73. Torzewski, M.; Rist, C.; Mortensen, R.F.; Zwaka, T.P.; Bienek, M.; Waltenberger, J.; Koenig, W.;
Schmitz, G.; Hombach, V.; Torzewski, J. C-reactive protein in the arterial intima: Role of C-reactive protein
receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2000, 20,
2094–2099. [CrossRef] [PubMed]
74. Zakynthinos, E.; Pappa, N. Inflammatory biomarkers in coronary artery disease. J. Cardiol. 2009, 53, 317–333.
[CrossRef] [PubMed]
75. Mach, F.; Lovis, C.; Gaspoz, J.M.; Unger, P.F.; Bouillie, M.; Urban, P.; Rutishauser, W. C-reactive protein as a
marker for acute coronary syndromes. Eur. Heart J. 1997, 18, 1897–1902. [CrossRef] [PubMed]
76. Kaptoge, S.; Di Angelantonio, E.; Lowe, G.; Pepys, M.B.; Thompson, S.G.; Collins, R.; Danesh, J. C-reactive
protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant
meta-analysis. Lancet 2010, 375, 132–140. [PubMed]
77. Van Wijk, D.F.; Boekholdt, S.M.; Wareham, N.J.; Ahmadi-Abhari, S.; Kastelein, J.J.; Stroes, E.S.; Khaw, K.T.
C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the
prospective EPIC-Norfolk cohort study. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 2888–2894. [CrossRef]
[PubMed]
78. Auer, J.; Berent, R.; Lassnig, E.; Eber, B. C-reactive protein and coronary artery disease. Jpn. Heart J. 2002, 43,
607–619. [CrossRef] [PubMed]
79. Habib, S.S.; Al Masri, A.A. Relationship of high sensitivity C-reactive protein with presence and severity of
coronary artery disease. Pak. J. Med. Sci. 2013, 29, 1425–1429. [CrossRef] [PubMed]
80. Ockene, I.S.; Matthews, C.E.; Rifai, N.; Ridker, P.M.; Reed, G.; Stanek, E. Variability and classification accuracy
of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin. Chem. 2001, 47, 444–450.
[PubMed]
81. Fedele, F.; Mancone, M.; Chilian, W.M.; Severino, P.; Canali, E.; Logan, S.; De Marchis, M.L.; Volterrani, M.;
Palmirotta, R.; Guadagni, F. Role of genetic polymorphisms of ion channels in the pathophysiology of
coronary microvascular dysfunction and ischemic heart disease. Basic Res. Cardiol. 2013, 108, 387. [CrossRef]
[PubMed]
82. Fedele, F.; Severino, P.; Bruno, N.; Stio, R.; Caira, C.; D’ambrosi, A.; Brasolin, B.; Ohanyan, V.; Mancone, M.
Role of ion channels in coronary microcirculation: A review of the literature. Future Cardiol. 2013, 9, 897–905.
[CrossRef] [PubMed]
Medicina 2018, 54, 36 12 of 13
83. Severino, P.; D’amato, A.; Netti, L.; Pucci, M.; De Marchis, M.; Palmirotta, R.; Volterrani, M.; Mancone, M.;
Fedele, F. Diabetes Mellitus and Ischemic Heart Disease: The Role of Ion Channels. Int. J. Mol. Sci. 2018,
19, 802. [CrossRef] [PubMed]
84. Qi, L.; Parast, L.; Cai, T.; Powers, C.; Gervino, E.V.; Hauser, T.H.; Hu, F.B.; Doria, A. Genetic susceptibility to
coronary heart disease in type 2 diabetes: 3 independent studies. J. Am. Coll. Cardiol. 2011, 58, 2675–2682.
[CrossRef] [PubMed]
85. Nikpay, M.; Goel, A.; Won, H.H.; Hall, L.M.; Willenborg, C.; Kanoni, S.; Saleheen, D.; Kyriakou, T.;
Nelson, C.P.; Hopewell, J.C.; et al. A comprehensive 1000 Genomes-based genome-wide association
meta-analysis of coronary artery disease. Nat. Genet. 2015, 47, 1121–1130. [CrossRef] [PubMed]
86. Vargas, J.D.; Manichaikul, A.; Wang, X.Q.; Rich, S.S.; Rotter, J.I.; Post, W.S.; Polak, J.F.; Budoff, M.J.;
Bluemke, D.A. Common genetic variants and subclinical atherosclerosis: The Multi-Ethnic Study of
Atherosclerosis (MESA). Atherosclerosis 2016, 245, 230–236. [CrossRef] [PubMed]
87. Campillo, A.; Roberts, R. Discovery of six new genetic risk variants predisposing to CAD. Cardiology
Today, June 2017. Available online: https://www.healio.com/cardiology/genetics-genomics/news/print/
cardiology-today/%7B26cd2dbc-9e44-4c5e-9c28-e35daa8011c3%7D/discovery-of-six-new-genetic-risk-
variants-predisposing-to-cad (accessed on 23 June 2017).
88. Barth, A.S.; Tomaselli, G.F. Gene scanning and heart attack risk. Trends Cardiovasc. Med. 2016, 26, 260–265.
[CrossRef] [PubMed]
89. Roberts, R. A Breakthrough in Genetics and its Relevance to Prevention of Coronary Artery Disease in LMIC.
Glob. Heart 2017, 12, 247–257. [CrossRef] [PubMed]
90. Schunkert, H.; Erdmann, J.; Samani, N.J. Genetics of myocardial infarction: A progress report. Eur. Heart J.
2010, 31, 918–925. [CrossRef] [PubMed]
91. So, H.C.; Gui, A.H.; Cherny, S.S.; Sham, P.C. Evaluating the heritability explained by known susceptibility
variants: A survey of ten complex diseases. Genet. Epidemiol. 2011, 35, 310–317. [CrossRef] [PubMed]
92. Samani, N.J.; Erdmann, J.; Hall, A.S.; Hengstenberg, C.; Mangino, M.; Mayer, B.; Dixon, R.J.; Meitinger, T.;
Braund, P.; Wichmann, H.E.; et al. Genomewide association analysis of coronary artery disease. N. Engl.
J. Med. 2007, 357, 443–453. [CrossRef] [PubMed]
93. Mcpherson, R.; Pertsemlidis, A.; Kavaslar, N.; Stewart, A.; Roberts, R.; Cox, D.R.; Hinds, D.A.;
Pennacchio, L.A.; Tybjaerg-Hansen, A.; Folsom, A.R.; et al. A common allele on chromosome 9 associated
with coronary heart disease. Science 2007, 316, 1488–1491. [CrossRef] [PubMed]
94. Helgadottir, A.; Thorleifsson, G.; Manolescu, A.; Gretarsdottir, S.; Blondal, T.; Jonasdottir, A.; Sigurdsson, A.;
Baker, A.; Palsson, A.; Masson, G.; et al. A common variant on chromosome 9p21 affects the risk of
myocardial infarction. Science 2007, 316, 1491–1493. [CrossRef] [PubMed]
95. Helgadottir, A.; Thorleifsson, G.; Magnusson, K.P.; Gretarsdottir, S.; Steinthorsdottir, V.; Manolescu, A.;
Jones, G.T.; Rinkel, G.J.; Blankensteijn, J.D.; Ronkainen, A.; et al. The same sequence variant on 9p21
associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet.
2008, 40, 217–224. [CrossRef] [PubMed]
96. Lanktree, M.B.; Hegele, R.A. Gene-gene and gene-environment interactions: New insights into the
prevention, detection and management of coronary artery disease. Genome Med. 2009, 1, 28. [CrossRef]
[PubMed]
97. Hartiala, J.; Schwartzman, W.S.; Gabbay, J.; Ghazalpour, A.; Bennett, B.J.; Allayee, H. The Genetic Architecture
of Coronary Artery Disease: Current Knowledge and Future Opportunities. Curr. Atheroscler. Rep. 2017, 19, 6.
[CrossRef] [PubMed]
98. Cole, C.B.; Nikpay, M.; Lau, P.; Stewart, A.F.; Davies, R.W.; Wells, G.A.; Dent, R.; Mcpherson, R. Adiposity
significantly modifies genetic risk for dyslipidemia. J. Lipid Res. 2014, 55, 2416–2422. [CrossRef] [PubMed]
99. Euesden, J.; Lewis, C.M.; O’reilly, P.F. PRSice: Polygenic Risk Score software. Bioinformatics 2015, 31,
1466–1468. [CrossRef] [PubMed]
100. Dudbridge, F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 2013, 9, e1003348.
[CrossRef]
101. Mega, J.L.; Stitziel, N.O.; Smith, J.G.; Chasman, D.I.; Caulfield, M.; Devlin, J.J.; Nordio, F.; Hyde, C.;
Cannon, C.P.; Sacks, F.; et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin
therapy: An analysis of primary and secondary prevention trials. Lancet 2015, 385, 2264–2271. [CrossRef]
Medicina 2018, 54, 36 13 of 13
102. Tada, H.; Melander, O.; Louie, J.Z.; Catanese, J.J.; Rowland, C.M.; Devlin, J.J.; Kathiresan, S.; Shiffman, D.
Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family
history. Eur. Heart J. 2016, 37, 561–567. [CrossRef] [PubMed]
103. Ganna, A.; Magnusson, P.K.; Pedersen, N.L.; De Faire, U.; Reilly, M.; Arnlov, J.; Sundstrom, J.; Hamsten, A.;
Ingelsson, E. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler. Thromb.
Vasc. Biol. 2013, 33, 2267–2272. [CrossRef] [PubMed]
104. Ripatti, S.; Tikkanen, E.; Orho-Melander, M.; Havulinna, A.S.; Silander, K.; Sharma, A.; Guiducci, C.;
Perola, M.; Jula, A.; Sinisalo, J.; et al. A multilocus genetic risk score for coronary heart disease: Case-control
and prospective cohort analyses. Lancet 2010, 376, 1393–1400. [CrossRef]
105. Thanassoulis, G.; Vasan, R.S. Genetic cardiovascular risk prediction: Will we get there? Circulation 2010, 122,
2323–2334. [CrossRef] [PubMed]
106. Wilson, P.W. Challenges to improve coronary heart disease risk assessment. JAMA 2009, 302, 2369–2370.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
